Evaluate the Safety, Tolerability, and Antiviral Activity of GLS4 With Ritonavir in Patients With Chronic HBV Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

February 28, 2019

Primary Completion Date

June 23, 2022

Study Completion Date

September 14, 2023

Conditions
Chronic HBV Infection
Interventions
DRUG

GLS4

Administered GLS4 120 mg orally three times daily in fed state

DRUG

RTV

Administered RTV 100 mg orally three times daily in fed state

DRUG

ETV

Administered orally ETV 0.5 mg once daily in fasted state

Trial Locations (37)

100020

Beijing Ditan Hospital Affiliated to Capital Medical University, Beijing

100044

Peking University People's Hospital, Beijing

100069

Beijing YouAn Hospital,Capital Medical University, Beijing

130012

The first hospital of jilin university, Changchun

130041

The second hospital of jilin university, Changchun

150001

The fourth affiliated hospital of Harbin medical university, Harbin

200020

Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai

200040

Huashan Sub-Hospital of Fudan University, Shanghai

200062

Shanghai putuo district central hospital, Shanghai

201500

Shanghai Public Health Clinical Center, Shanghai

210002

The People's Liberation Army No.81 Hospital, Nanjing

210003

The Second Hospital of Nanjing, Nanjing

210008

Nanjing Gulou Hospital, Nanjing

212004

The Third People's Hospital of Zhenjiang, Zhenjiang

266011

Qingdao municipal hospital, Qingdao

300170

Tianjin third central hospital, Tianjing

325000

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou

350025

Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou

400010

The second affiliated hospital of ChongQing medical university, Chongqing

400042

The first affiliated hospital of ChongQing medical university, Chongqing

410008

Xiangya Hospital, Central South University, Changsha

430010

The Central Hospital of Wuhan, Wuhan

430022

Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology, Wuhan

430030

Tongji Hospital Affiliated to Tongji Medical College of Huazhong University Science & Technology, Wuhan

450003

Henan Provincial People's Hospital, Zhengzhou

510060

Guangzhou Eighth People's Hospital, Guangzhou

510515

Nanfang Hospital of Southern Medical University, Guangzhou

510630

The third affiliated hospital of sun yat-sen university, Guangzhou

530021

The first affiliated hospital of Guangxi medical university, Nanning

550001

Affiliated hospital of Guizhou medical university, Guiyang

563000

Affiliated hospital of ZunYi medical college, Zunyi

570311

Hainan General Hospital, Haikou

610041

West China Hospital, Sichuan University, Chengdu

610072

Sichuan Provincial People's Hospital, Chengdu

710038

The second affiliated hospital of air force medical university, Xi’an

710061

The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an

730000

The First Hospital of Lanzhou University, Lanzhou

All Listed Sponsors
lead

Sunshine Lake Pharma Co., Ltd.

INDUSTRY

NCT04147208 - Evaluate the Safety, Tolerability, and Antiviral Activity of GLS4 With Ritonavir in Patients With Chronic HBV Infection | Biotech Hunter | Biotech Hunter